CoronaryAtlas logo
CoronaryAtlas
CK-MB
Pathway / Myocardial injury (shared endpoint)

CK-MB

CKMprotein

CK-MB is a cardiac enzyme released following myocardial necrosis and serves as a diagnostic and prognostic biomarker of infarct size and adverse outcomes in acute MI.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencehigh
RationaleCardiac-specific isoform of creatine kinase released upon cardiomyocyte necrosis; AMI diagnostic and prognostic marker.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableNo
EnsemblENSG00000104879

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
61
A — assay feasibility
96
E — evidence strength
100
T1DI (composite)
62
Specificity differential (R−C)+30.1
Direct evidence: higher in Type I (D=+2)
CK-MB mean RULN 9 (Type 1 MI) vs 4 (Type 2 MI), P=0.002; also higher % rise in T1MI vs T2MI
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossmag 0
2hypovolemia / dehydrationmag 2
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 1
2high-demand / peri-operative stressmag 2
3sudden cardiac deathmag 2
4aPCI-related periproceduralmag 2
4bstent thrombosismag 3
4cin-stent restenosismag 2
5CABG-relatedmag 2
Coverage: 11/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 28 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top)
Method / principle
Chemiluminescent sandwich immunoassay (mass); or enzymatic activity
Reagent / substrate
Anti-CK-MB antibody pair (mass); or CK-MB immunoinhibition + coupled hexokinase/G6PD (activity)
Platform
Automated core-lab analyzer
Turnaround · availability
STAT–routine · FDA-cleared

Literature evidence(50)

Clinical trials(1)